uniQure (QURE) drew fresh investor focus after announcing plans to seek UK regulatory approval for its AMT-130 gene therapy, supported by Phase 1/2 data indicating a 75% slowing of Huntington’s disease progression at a high dose.

The stock has pulled back slightly in the last week, with a 7 day share price return of a 2.97% decline. However, the 30 day share price return of 34.17% and 1 year total shareholder return of 59.56% point to solid underlying momentum.

If gene therapy is on your radar, this is a good moment to widen your watchlist and see which healthcare AI stocks are starting to stand out through the 34 healthcare AI stocks.

With uniQure shares up 34.17% over the past month and 59.56% over the past year, yet trading at a 61% discount to the average analyst price target, you have to ask: is there still a buying opportunity here, or is the market already pricing in future growth?

Most Popular Narrative: 38% Undervalued

With uniQure closing at $24.19 versus a narrative fair value of $39.05, the gap between market price and expectations is wide enough to warrant a closer look at the core assumptions behind that figure.

The potential accelerated approval for AMT-130 in treating Huntington's disease could significantly boost future revenues as it would be one of the first disease-modifying treatments available for this condition.

Want to see what is sitting behind that valuation gap? The narrative leans heavily on rapid revenue expansion, margin repair and a future earnings multiple that assumes strong execution on AMT-130 and the broader pipeline.

Result: Fair Value of $39.05 (UNDERVALUED)

However, you still need to weigh the FDA’s preference for a sham surgery Phase 3 trial and uniQure’s reliance on AMT-130 as key pressure points.

Another View: What The P/B Ratio Is Saying

The narrative fair value suggests upside, but the current P/B of 10.2x is far above the US Biotechs average of 2.5x, even though it is below the 15.8x peer average. That gap points to real valuation risk if expectations are not met. Which signal do you trust more?

Next Steps

Given the mix of optimism and concern in this story, it makes sense to scan the numbers yourself and pressure test the assumptions quickly. To balance the potential upside with the issues investors are watching, take a look at the 1 key reward and 4 important warning signs

Ready to find more ideas worth your attention?

Do not stop with a single stock. Use proven filters to quickly surface other opportunities that match your goals before the crowd pays attention.

• Target resilience by scanning companies with healthy finances through the solid balance sheet and fundamentals stocks screener (46 results).
• Spot mispriced potential by checking out the screener containing 21 high quality undiscovered gems before others catch on.
• Prioritise capital protection by reviewing 69 resilient stocks with low risk scores that keep risk scores in focus.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.